Current Headlines

  1. Researchers Discover All-New Antifungal Drug Candidate In McMaster's Greenhouse 8/11/2025

    A research team at McMaster University has discovered a new drug class that could someday lead to breakthrough treatments for dangerous fungal infections.

  2. New Cancer Drug Boosts Effectiveness Of Chemotherapy – Even In Resistant Tumours 8/11/2025

    A groundbreaking cancer drug could enhance how patients respond to chemotherapy even in treatment-resistant tumours.

  3. Arvinas Announces FDA Acceptance Of The New Drug Application For Vepdegestrant For The Treatment Of ESR1m, ER+/HER2- Advanced Breast Cancer 8/8/2025

    Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vepdegestrant for the treatment of patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy.

  4. MAXONA Pharmaceuticals Submits Investigational New Drug Application To The U.S. Food And Drug Administration For MAX-001 8/7/2025

    MAXONA Pharmaceuticals today announced that the company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for the company's lead compound, MAX-001, for the treatment of acute pain.

  5. XtalPi And DoveTree Announce Landmark $6B AI Drug Discovery Collaboration 8/6/2025

    XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine.

  6. Cingulate Submits New Drug Application To FDA For Lead ADHD Asset CTx-1301 8/6/2025

    Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has submitted its New Drug Application (NDA) to the U.S.

  7. AI Research Targets Faster Drug Development 8/6/2025

    Junzhou Huang, Jenkins Garrett Endowed Professor in the Department of Computer Science and Engineering at The University of Texas at Arlington, has received a major federal grant to advance the use of artificial intelligence in antibody drug discovery—research that could help accelerate the medical response to future pandemics.

  8. Nxera Launches Broad Proprietary Pipeline Targeting Obesity And Chronic Weight Management 8/5/2025

    Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders.

  9. Alveolus Bio Secures Strategic Investment From Shilpa Medicare To Advance Groundbreaking Pulmonary Therapeutics 8/4/2025

    Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation.

  10. Innovent Receives U.S. FDA Approval For IND Application Of Oral GLP-1R Agonist IBI3032 8/4/2025

    Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S.